ClinicalTrials.gg
CompletedNCT00419393Updated Sep 5, 2014Results posted

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

A Phase 3 interventional study of Keppra XR (Levetiracetam XR) in Epilepsy, sponsored by UCB Pharma. Completed at 37 sites in 4 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-05.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
19th of 60
190 · median 94
Started
2007
with 6 others
Phase 3
28 of 60
2 open now
Registered
19th of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 19th largest by enrollment, is one of 7 that started in 2007, is one of 28 in phase 3, and was the 19th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.

03

Conditions studied

  • Epilepsy

Keywords

  • Keppra XR
  • Levetiracetam XR
  • long term
  • partial seizures
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who were randomized into study N01280 [NCT00419094], and completed the 2 week up titration period

Exclusion criteria

Exclusion Criteria:

  • Subjects who did not meet the inclusion/exclusion criteria for N01280 [NCT00419094]
  • Subjects who were discontinued prior to the end of titration period
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Keppra XR (Levetiracetam XR)

    1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)

    Drug: Keppra XR (Levetiracetam XR)

Interventions

  • 500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).

    Also known as: Keppra XR

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Duration of the Treatment Period (6 months-2 years)

  2. Number of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)

    A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.

    Time frame: Duration of the Treatment Period (6 months-2 years)

  3. Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event During the Actual Treatment Period

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Duration of the Treatment Period (6 months-2 years)

Secondary outcomes

  1. Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 6 Months

    Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 6 months.

    Time frame: Study entry through 6 months

  2. Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 12 Months

    Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 12 months.

    Time frame: Study entry through 12 months

07

Results

Posted Jul 13, 2011

Participant flow

The study began December 2007 recruiting in the United States, Poland, Mexico, and the Russian Federation. The study completed March 2010.

Participant flow — Overall Study
MilestoneKeppra XR (Levetiracetam XR)
Started190
Completed166
Not completed24
Withdrew: Adverse event5
Withdrew: Protocol violation5
Withdrew: Withdrawal by subject7
Withdrew: Other: sponsor request3
Withdrew: Other: subject had temporal lobectomy1
Withdrew: Other: site closure1
Withdrew: Other: other health problems1
Withdrew: Other: investigator decision1

Outcome measures

PrimaryNumber of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Time frame:
Duration of the Treatment Period (6 months-2 years)
Reported as:
Number · number of subjects
Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)
number of subjectsKeppra XR
Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)126
PrimaryNumber of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)

A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.

Time frame:
Duration of the Treatment Period (6 months-2 years)
Reported as:
Number · number of subjects
Number of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)
number of subjectsKeppra XR
Number of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)22
PrimaryNumber of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event During the Actual Treatment Period

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Time frame:
Duration of the Treatment Period (6 months-2 years)
Reported as:
Number · number of subjects
Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event During the Actual Treatment Period
number of subjectsKeppra XR
Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event During the Actual Treatment Period5
SecondaryPercentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 6 Months

Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 6 months.

Time frame:
Study entry through 6 months
Reported as:
Number · percentage of subjects
Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 6 Months
percentage of subjectsKeppra XR
Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 6 Months77.0
SecondaryPercentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 12 Months

Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 12 months.

Time frame:
Study entry through 12 months
Reported as:
Number · percentage of subjects
Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 12 Months
percentage of subjectsKeppra XR
Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 12 Months65.3

Adverse events

Collected over Up to two years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Keppra XR (Levetiracetam XR)—22/189 (11.6%)57/189 (30.2%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventKeppra XR (Levetiracetam XR)
ConvulsionNervous system disorders4/189
Chest painGeneral disorders2/189
Angina pectorisCardiac disorders1/189
Abdominal painGastrointestinal disorders1/189
DrowningGeneral disorders1/189
Non-cardiac chest painGeneral disorders1/189
Bile duct stoneHepatobiliary disorders1/189
CholangitisHepatobiliary disorders1/189
CholecystitisHepatobiliary disorders1/189
Hepatic cirrhosisHepatobiliary disorders1/189
Most frequent other events
Most frequent other events
EventKeppra XR (Levetiracetam XR)
HeadacheNervous system disorders26/189
NasopharyngitisInfections and infestations15/189
SomnolenceNervous system disorders15/189
InfluenzaInfections and infestations14/189
DizzinessNervous system disorders10/189
CoughRespiratory, thoracic and mediastinal disorders10/189

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Keppra XR (Levetiracetam XR)
<=18 years40
Between 18 and 65 years147
>=65 years3
Age, Continuous
Age, Continuous(years)Keppra XR (Levetiracetam XR)
Mean33.44 ± 14.46
Sex: Female, Male
Sex: Female, Male(Participants)Keppra XR (Levetiracetam XR)
Female111
Male79
Region of Enrollment
Region of Enrollment(participants)Keppra XR (Levetiracetam XR)
United States26
Mexico49
Poland59
Russian Federation56
08

Study locations

37 sites
  • Dothan, Alabama, United States
  • Northport, Alabama, United States
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Bakersfield, California, United States
  • Loxahatchee, Florida, United States
  • Atlanta, Georgia, United States
  • Suwanee, Georgia, United States
  • Witchita, Kansas, United States
  • Detroit, Michigan, United States
  • Camden, New Jersey, United States
  • Buffalo, New York, United States
  • Cedarhurst, New York, United States
  • Toledo, Ohio, United States
  • Tulsa, Oklahoma, United States
  • San Antonio, Texas, United States
  • Aguascalientes, Mexico
  • Guadalajara Jalisco, Mexico
  • Guadalajara, Mexico
  • Mexico City, Mexico
  • Mexico DF, Mexico
  • Monterrey, Mexico
  • Bialystok, Poland
  • Gdansk, Poland
  • Katowice, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Poznan, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Kalingrad, Russian Federation
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Samara, Russian Federation
  • St Petersburg, Russian Federation
  • St. Petersburg, Russian Federation
  • Yaroslavl, Russian Federation
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2007
First posted
Jan 8, 2007
Start
Dec 2007
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jul 13, 2011
Last update
Sep 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00419393
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 8, 2007
Start date
Dec 2007
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jul 13, 2011
Last update
Sep 5, 2014

Study contacts

UCB Clinical Trial Call Center, MD
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion